Foresight Biotherapeutics Pulls in $2 Million

Xconomy New York — 

Foresight Biotherapeutics, a New York company developing new therapies to treat eye and ear disorders, has raised $2 million, according to an SEC filing. Foresight’s technology platform, called Povidone-Iodine (PVP-I), allows a well-known antiseptic to be formulated in different ways. The company’s lead experimental compound is being tested in a form of conjunctivitis. The company was co-founded by Jason Stein and Michael Weiser, who are also the founders of Actin Biomed, a healthcare investment firm.